Year: 2024

Preliminary Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with approximately $107 million in cash and cash equivalents Expects to finish 2024 with $65 million or more in cash and cash equivalents Withdraws formal revenue guidance due to recent growth headwind from U.S. FDA’s late-Q3 2024 warning on potential for substantially reduced activity of pemivibart through the PEMGARDA Fact Sheet and other media based on contested, third-party, non-peer-reviewed, non-reproducible, virologic activity data from a non-pemivibart antibody Targets near-term (1H 2025) profitability with existing cash and cash equivalents, anticipated growth of net product revenue, and various operational efficiency improvements Further update to be provided on Q3 2024 earnings callWALTHAM, Mass., Oct. 29, 2024 (GLOBE...

Following strong protection (84% relative risk reduction versus placebo) demonstrated through month 6 with pemivibart, CANOPY clinical trial participants were followed for an additional six-month period (months 7-12), with no additional doses, to assess safety and efficacy as drug concentrations declined over time In the six-month off-drug follow-up period (months 7-12), substantially reduced concentrations of PEMGARDA reduced the risk of symptomatic COVID-19 by 64% compared to placebo in an immunocompetent adult population, for total twelve-month risk reduction of 76% following two initial pemivibart doses (nominal p

BURLINGTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced it will report financial results for the third quarter 2024 and provide business updates on Tuesday, November 12, 2024, at 4:30 p.m. ET. A live webcast of the conference call can be accessed in the “Events” section of Fractyl’s website at https://ir.fractyl.com/. The webcast will be archived and available for replay following the live event. About Fractyl Health         Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity...

Premier Event to Showcase Growth Companies and Foster High-Level Investor Engagement MILTON, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) — Sono-Tek Corporation (Nasdaq: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today announced its participation in Spartan Capital Securities, LLC’s inaugural investor conference on November 4th at the Pierre Hotel in New York. Steve Harshbarger, CEO & President of Sono-Tek will provide a formal presentation to investor attendees at 2:20 PM ET. To schedule a one-on-one meeting please register to attend at the link below. For more information about the conference and registration details, please visit Spartan Capital’s conference page. About Spartan Capital Securities, LLC Spartan Capital Securities, LLC, is a premier full-service financial firm offering...

DALLAS, Oct. 29, 2024 (GLOBE NEWSWIRE) — Beneficient (Nasdaq: BENF) (“Ben” or the “Company”), a technology-enabled financial services holding company, today announced that it will be presenting at the LD Micro Main Event XVII investor conference to be held October 28-30, 2024 in Los Angeles. As part of the conference, the Company will conduct a group presentation at 12:30 pm Pacific Time on Wednesday, October 30, 2024. To join the presentation online, please visit the webcast link available at  https://shareholders.trustben.com/. Additionally, Beneficient will host investor meetings throughout the day on Wednesday, October 30, 2024. Investors attending the conference in person may request meetings with Beneficient through LD Micro’s meeting portal or Beneficient’s IR contact, mkreps@darrowir.com. Qualified investors who would...

5.37% Fixed Rate for 5 Years, Interest Only, on $525M Loan Lowest Refi Rate Achieved by Company in Past 5 Years SANTA MONICA, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) —  Macerich (NYSE: MAC), one of the nation’s leading owners, operators and developers of major retail properties in top markets, today announced that it has refinanced fortress property Queens Center at highly favorable terms with a new $525 million loan bearing fixed interest of 5.37% and interest-only payments during the entire term. “We are pleased to share details on our just-completed refinance of Queens Center, consistently one of the best-performing properties in our entire portfolio,” said Jack Hsieh, President and Chief Executive Officer, Macerich. “5.37% is the lowest rate on a refinance that Macerich has achieved since 2019, and this loan represents Macerich’s...

– Company to Hold Virtual Special Meeting of Shareholders on November 20, 2024 – This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated March 8, 2024, to its short form base shelf prospectus dated November 10, 2023. TORONTO, Ontario and BROSSARD, Québec, Oct. 29, 2024 (GLOBE NEWSWIRE) — Bitfarms Ltd. (NASDAQ/TSX: BITF) (“Bitfarms” or the “Company”), a global leader in vertically integrated Bitcoin data center operations, today announced that it has nominated Andrew J. Chang for election to its Board of Directors (the “Board”) at the Special Meeting of shareholders to be held on November 20, 2024 at 4:00p.m. Eastern Time (the “Special Meeting”). Bitfarms Special Meeting of Shareholders Pursuant to the Settlement Agreement between the Company and Riot Platforms,...